Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Misaki Kiguchi

Vascular Surgery Washington, DC Medical Doctor

NPI 1811150832 CMS profile 1350423

106 Irving St Nw, Pob North, Suite 3150, Washington, DC 20010

Open in the dashboard

General payments

$186,809

303 records reported · program years 2019–2025

Research payments

$425

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$161,278 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Misaki Kiguchi of Washington, DC is reported in the CMS Open Payments database as having received $186,809 across 303 general payments and $425 in research payments paid to them. Separately, studies naming them as principal investigator received $161,278 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $42,831 48
2024 General $41,017 52
2024 Research $425 1
2023 General $37,264 37
2022 General $36,527 65
2021 General $18,510 52
2020 General $6,455 19
2019 General $4,204 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Misaki Kiguchi
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Misaki Kiguchi were reported at $42,831. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Misaki Kiguchi Vascular Surgery median Middle half National median
2019 $4,204 $796 $226–$2,363 $163
2020 $6,455 $348 $118–$1,110 $114
2021 $18,510 $471 $158–$1,421 $132
2022 $36,527 $725 $222–$2,183 $149
2023 $37,264 $836 $257–$2,440 $160
2024 $41,017 $909 $252–$2,619 $164
2025 $42,831 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $146,950 194 payments
  2. Boston Scientific Corporation $27,842 43 payments
  3. Medtronic Vascular, Inc. $9,772 26 payments
  4. W. L. Gore & Associates, Inc. $598 6 payments
  5. KCI USA, Inc $400 1 payment
  6. Cook Medical LLC $387 7 payments
  7. Inari Medical, Inc. $213 6 payments
  8. Abbott Laboratories $142 3 payments
  9. Philips Electronics North America Corporation $118 1 payment
  10. Bard Peripheral Vascular, Inc. $77 4 payments
  11. Other $310 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $145,163 46 payments
  2. Consulting Fee $18,481 12 payments
  3. Travel and Lodging $14,473 63 payments
  4. Food and Beverage $7,740 179 payments
  5. Education $952 3 payments
Products named General payments · program years 2019–2025
  1. VENASEAL EndoVenous Therapies $91,737 95 payments
  2. ClosureFast $29,485 20 payments
  3. Varithena Administration Pack $20,476 13 payments
  4. VenaSeal EndoVenous Therapies $14,225 20 payments
  5. VenaSeal EndoVenous Therapies $9,492 20 payments
  6. IN.PACT Admiral $4,946 18 payments
  7. ClosureRFS $4,200 1 payment
  8. General - Therapies $2,500 2 payments
  9. Abre $1,696 24 payments
  10. PREVENA $400 1 payment
  11. Other $3,938 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $425 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

53

Median for Vascular Surgery: 122

Drug cost

$34,050

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 15 $18,901
Xarelto Rivaroxaban Brand 13 $14,580
Clopidogrel Clopidogrel Bisulfate Brand 25 $569

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$363,911

Medicare's payments for the services billed

Medicare patients

1,508

Average age 76

Services billed

2,918

902 women, 606 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 42%
Diabetes 39%
Chronic kidney disease 37%
Heart failure 27%
Atrial fibrillation 22%
Cancer 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

304 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record